1. Indaptus raises $6 million from investor David E. Lazar. 2. Lazar appointed Co-CEO and Chairman, emphasizing strategic opportunities. 3. Shares of convertible preferred stock to be issued pending shareholder approval. 4. Board reconstitution includes new members, reflecting organizational changes. 5. Decoy platform shows promising pre-clinical results for cancer and viral infections.
FAQ
Why Bullish?
The $6 million investment suggests confidence in Indaptus' potential, mirroring positive stock movements after similar capital raises in biotech. For instance, similar companies often see stock price gains post-strategic funding announcements.
How important is it?
The announcement of funding and leadership changes is crucial for market perception, affecting investor confidence and sharing dynamics, especially in the biotech sector where leadership and capital clarity are vital for stock performance.
Why Short Term?
Immediate effects expected from the stock purchase agreement and board changes, particularly as they relate to upcoming shareholder approvals. Short-term fluctuations can follow investor sentiment influenced by leadership and capital strategies.
Indaptus Therapeutics Enters $6 Million Securities Purchase Agreement with David E. Lazar
On December 29, 2025, Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology firm focused on innovative treatments for cancer and viral infections, announced the execution of a $6 million securities purchase agreement with investor David E. Lazar. This agreement involves the acquisition of non-voting convertible preferred stock, marking a significant landmark for the company and its shareholders.
Appointment of David E. Lazar
As part of this transaction, Mr. Lazar has been appointed Co-Chief Executive Officer and Chairman of the Board at Indaptus. Alongside him, Jeffrey Meckler will continue serving as Co-CEO and remain on the Board.
Mr. Lazar expressed his enthusiasm regarding this investment, stating, *“In making this significant investment in Indaptus, I look forward to continuing to evaluate the Company’s lead product candidate while actively exploring strategic opportunities to drive value for our stockholders.”* He also acknowledged the Board's unanimous support for this initiative.
Details of the Securities Purchase Agreement
Under the terms of the agreement, Indaptus will issue a total of 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of non-voting convertible Series AAA preferred stock in exchange for Mr. Lazar's investment of $6.0 million. Each share of Series AA Preferred Stock is convertible into 20 shares of common stock, while each Series AAA Preferred Stock share can be converted into 150 shares.
The conversion of these shares is contingent upon obtaining stockholder approval at the upcoming stockholder meeting, expected to occur in the first quarter of 2026. The closing of this transaction took place on December 23, 2025.
Board Reconstitution Following the Agreement
Concurrently with this agreement, Indaptus restructured its Board of Directors. Mr. Lazar's appointment as Chairman was followed by Avraham Ben-Tzvi joining the Board, replacing **Hila Kara** and **Dr. Robert Martell**, who both stepped down. Following stockholder approval, Mr. Lazar will have the opportunity to nominate up to three additional directors.
About Indaptus Therapeutics
Indaptus Therapeutics has made strides in the field of immunotherapy, developing a patented technology designed to efficiently activate both innate and adaptive immune responses. Its unique Decoy platform utilizes non-pathogenic, Gram-negative bacteria to deliver multiple immune signals safely via intravenous administration.
Indaptus' product candidates are designed to minimize toxicity while effectively activating various immune pathways. Their approach shows promise in preclinical models, demonstrating significant activity against various cancers and chronic viral infections such as chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV).
Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements as defined by the Private Securities Litigation Reform Act. These statements involve inherent risks and uncertainties, including but not limited to the potential success of stockholder approvals and the company's future strategic endeavors.
Factors that could lead to actual results differing materially from these forward-looking statements include the risk of not obtaining necessary approvals, uncertainties in pursuing strategic alternatives, and the company’s ability to manage operational funding. Investors are encouraged to view the full report and keep abreast of developments related to INDP.